Related Experiment Video
Updated: Jan 2, 2026
Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
Epinecidin-1 Protects against Methicillin Resistant Staphylococcus aureus Infection and Sepsis in Pyemia Pigs
Han-Ning Huang1, Chieh-Yu Pan2, Bor-Chyuan Su3
1Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10 Dahuen Road, Jiaushi, Ilan 262, Taiwan.
Abstract:
Methicillin resistant Staphylococcus aureus (MRSA) may be found on the skin, nose, and throats of long-term hospitalized patients. While MRSA infections are usually minor, serious infections and death may occur in immunocompromised or diabetic patients, or after exposure of MRSA to blood. This report demonstrates that the antimicrobial peptide (AMP) epinecidin-1 (Epi-1) efficiently protects against MRSA infection in a pyemia pig model. We first found that Epi-1 exhibits bactericidal activity against MRSA. Next, pharmacokinetic analysis revealed that Epi-1 was stable in serum for 4 h after injection, followed by a gradual decrease. This pharmacokinetic profile suggested Epi-1 may bind serum albumin, which was confirmed in vitro. Harmful effects were not observed for doses up to 100 mg/kg body weight in pigs. When Epi-1 was supplied as a curative agent 30 min post-infection, MRSA-induced abnormalities in blood uric acid (UA), blood urea nitrogen (BUN), creatine (CRE), GOT, and GPT levels were restored to normal levels. We further showed that the bactericidal activity of Epi-1 was higher than that of the antibiotic drug vancomycin. Epi-1 significantly decreased MRSA counts in the blood, liver, kidney, heart, and lungs of infected pigs. Elevated levels of serum C reactive protein (CRP), proinflammatory cytokine IL6, IL1β, and TNFα were also attenuated by Epi-1 treatment. Moreover, the MRSA genes, enterotoxin (et)-A, et-B, intrinsic methicillin resistance A (mecA), and methicillin resistance factor A (femA), were significantly reduced or abolished in MRSA-infected pigs after treatment with Epi-1. Hematoxylin and eosin staining of heart, liver, lung, and kidney sections indicated that Epi-1 attenuated MRSA toxicity in infected pigs. A survival study showed that the pyemia pigs infected with MRSA alone died within a week, whereas the pigs post-treated with 2.5 mg/kg Epi-1 were completely protected against death. The present investigation, thus, demonstrates that Epi-1 effectively protects pyemia pigs against pathogenic MRSA without major toxic side effects.
Insights
Epinecidin-1 (Epi-1) effectively combats Methicillin-resistant Staphylococcus aureus (MRSA) infections in pigs, showing higher efficacy than vancomycin. This antimicrobial peptide (AMP) demonstrates significant protection against MRSA, even preventing death with minimal side effects.
Area of Science:
- Microbiology
- Pharmacology
- Immunology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat, particularly to hospitalized patients, leading to severe infections and mortality in vulnerable individuals.
- Existing treatments face challenges due to emerging resistance and potential side effects, necessitating the development of novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of the antimicrobial peptide epinecidin-1 (Epi-1) as a treatment for MRSA infections.
- To compare the therapeutic potential of Epi-1 against MRSA with the current standard antibiotic, vancomycin.
Main Methods:
- In vitro assessment of Epi-1's bactericidal activity against MRSA.
- Pharmacokinetic analysis of Epi-1 in a pyemia pig model, including serum stability and albumin binding.
- In vivo efficacy studies in MRSA-infected pigs, monitoring clinical signs, biochemical markers, inflammatory cytokines, gene expression, and survival rates.
Main Results:
- Epi-1 demonstrated potent bactericidal activity against MRSA and was stable in pig serum for 4 hours.
- Treatment with Epi-1 restored MRSA-induced biochemical abnormalities, significantly reduced bacterial load in organs, and attenuated inflammatory responses.
- Epi-1 exhibited superior efficacy to vancomycin, reduced MRSA virulence gene expression, and completely protected pigs from MRSA-induced mortality at a dose of 2.5 mg/kg.
Conclusions:
- Epinecidin-1 is a highly effective antimicrobial peptide for treating MRSA infections, offering significant therapeutic benefits over vancomycin.
- Epi-1 demonstrates a favorable safety profile, with no observed toxic effects at therapeutic doses, making it a promising candidate for clinical development.
- The study validates Epi-1 as a potent agent against MRSA, highlighting its potential to address the growing challenge of antibiotic resistance.
